Prednisolone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Prednisolone: From Corticosteroid Anti-Inflammatory Therapy to Alopecia Areata
One-Sentence Summary
Prednisolone is a systemic corticosteroid broadly used for its anti-inflammatory and immunosuppressive effects; a specific SAHPRA-registered original indication is not available in this evidence pack because the drug is currently not marketed in South Africa under this evaluation. The TxGNN model predicts it may be effective for Alopecia Areata, with 18 indexed clinical trial records (a subset directly on-topic) and 20 publications currently supporting this direction, including corticosteroid-specific pulse-therapy studies in alopecia areata.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available from SAHPRA licensing data (0 registrations found). Prednisolone is broadly known as a systemic corticosteroid used for inflammatory, allergic and autoimmune conditions. |
| Predicted New Indication | Alopecia Areata |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L3 |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, prednisolone is a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive activity, used across a wide range of therapeutic areas rather than a single narrow indication.
Alopecia areata is an autoimmune disease driven by CD8+ T-cell infiltration around the hair follicle and a Th1/IFN-γ-dominant immune attack. Systemic corticosteroids — including pulsed prednisolone/methylprednisolone regimens — are already used in real-world clinical practice as a treatment option for moderate-to-severe alopecia areata, which supports the biological plausibility of this TxGNN prediction even though it falls outside prednisolone’s conventionally registered indications.
Because both the mechanism of action and the original registered indication are data gaps in this pack, the reasoning here rests primarily on prednisolone’s known corticosteroid class effect and on existing clinical literature describing corticosteroid pulse therapy in alopecia areata (see Literature Evidence below), rather than on a documented original-indication-to-new-indication pathway.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01167946 | Phase 4 | Completed | 42 | Oral mega-pulse methylprednisolone at higher doses/frequency evaluated in severe, therapy-resistant alopecia areata (totalis/universalis/ophiasic types not previously responsive to standard pulse dosing). |
| NCT07101471 | N/A (observational) | Completed | 296 | Real-world safety/effectiveness study of tofacitinib in alopecia, with participants receiving tofacitinib with or without adjuvant prednisolone; no comparator arm. |
| NCT01017510 | N/A | Unknown | 20 | Compared DERMOJET needle-free injector vs. standard syringe for intralesional (local) corticosteroid delivery in alopecia areata — a delivery-technique study, not systemic prednisolone. |
Note: 15 additional trials returned by the search (mostly Phase 2/3 studies of biologics such as baricitinib, anifrolumab and rituximab in systemic lupus erythematosus) were graded low relevance (Grade C) — they involve different drugs and a different disease, and are excluded from this table.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15692475 | 2005 | RCT | J Am Acad Dermatol | Placebo-controlled trial of oral pulse prednisolone in alopecia areata — one of the few randomized, placebo-controlled studies in this field. |
| 37870096 | 2023 | Review (Network Meta-analysis) | Cochrane Database Syst Rev | Network meta-analysis comparing treatments for alopecia areata, including immunosuppressants (corticosteroids), hair-growth stimulants and contact immunotherapy. |
| 30191561 | 2019 | Systematic Review | Australas J Dermatol | Systematic review (1946–2018) of systemic treatments for alopecia areata, totalis and universalis, evaluating RCT-level evidence. |
| 37992355 | 2023 | Review | Dermatol Pract Concept | Reviews efficacy, relapse rates, side effects and prognostic factors of corticosteroid pulse regimens in alopecia areata. |
| 41243342 | 2025 | Review | J Dermatolog Treat | Focused review on dexamethasone oral mini-pulse therapy achieving durable remission in severe alopecia areata when JAK inhibitors are unavailable or unsuitable. |
| 21572877 | 2009 | Cohort/Case Series | Dermatoendocrinology | Medium-dose oral prednisolone pulse therapy effective in early-stage alopecia areata, limited by significant steroid-related side effects. |
| 35986630 | 2022 | Cohort (Retrospective) | Dermatol Ther | Retrospective comparison of methylprednisolone alone vs. methylprednisolone + methotrexate in 26 patients with extensive alopecia areata. |
| 36461625 | 2023 | Cohort (Retrospective/Review) | Pediatr Dermatol | Review of pulse-dose corticosteroid dosing regimens and associated side effects in pediatric alopecia areata. |
| 26179196 | 2015 | Cohort | Dermatol Ther | Long-term follow-up (median 96 months) of 65 children/adolescents with severe alopecia areata treated with combined oral pulse + topical corticosteroids. |
| 28140540 | 2017 | Case Series | J Dtsch Dermatol Ges | Sequential high- then low-dose systemic corticosteroid therapy for severe childhood alopecia areata; rapid initial response but relapse common after discontinuation. |
South Africa Market Information
No SAHPRA product registrations were found in this evidence pack (0 of 0 licenses). Prednisolone’s market status is recorded as Not Marketed under this candidate — this should be verified directly against the current SAHPRA product register before any repurposing pathway is pursued, since prednisolone is a widely used generic corticosteroid internationally.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale:
- Literature evidence includes a placebo-controlled trial and multiple cohort/case-series studies specifically evaluating oral pulse prednisolone/methylprednisolone in alopecia areata, plus systematic reviews confirming corticosteroids as an established (if not first-line) treatment option — consistent with an L3 evidence level (observational studies/systematic reviews, no completed Phase 2/3 RCT specifically powered for this indication).
To proceed, the following is needed:
- Official Professional Information (PI) / label warnings and contraindications for prednisolone — currently a blocking data gap that prevents an initial safety (S1) assessment.
- Confirmation of prednisolone’s current SAHPRA registration and market status (this evidence pack shows 0 registrations, which should be independently verified given its status as a common generic).
- Detailed mechanism of action data to strengthen the mechanistic rationale linking corticosteroid immunosuppression to alopecia areata pathophysiology.
- A dedicated randomized controlled trial (Phase 2/3) of prednisolone specifically in alopecia areata to raise the evidence level beyond L3.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.